Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Other Non Operating Income (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other Non Operating Income for 4 consecutive years, with $1922.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 200.31% to $1922.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40490.0 through Dec 2025, up 172.95% year-over-year, with the annual reading at $40490.0 for FY2025, 292.23% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $1922.0 at bioAffinity Technologies, up from $513.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $212258.0 in Q2 2022, with the low at -$1281.0 in Q4 2023.
  • Average Other Non Operating Income over 4 years is $24627.9, with a median of $1922.0 recorded in 2025.
  • Peak annual rise in Other Non Operating Income hit 3805200.0% in 2025, while the deepest fall reached 99.96% in 2025.
  • Over 4 years, Other Non Operating Income stood at $212258.0 in 2022, then tumbled by 100.6% to -$1281.0 in 2023, then soared by 149.96% to $640.0 in 2024, then surged by 200.31% to $1922.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $1922.0, $513.0, and $38053.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.